A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Clinical trial NCT03596294 · COMPLETED

Trial details

NCT number: NCT03596294
Sponsor: Idorsia Pharmaceuticals Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Subjects

Start date: 2018-07-19
Primary completion: 2018-08-03
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.